Coverage
Billing and reimbursement information
The Merck Access Program for ZINPLAVA can help answer questions about:
- - Insurance coverage for patients
- - Benefit investigations
- - Prior authorizations
- - Appeals
- - Coding and billing
ZINPLAVA™
(bezlotoxumab) injection 25 mg/mL
Coverage
The Merck Access Program for ZINPLAVA can help answer questions about:
or
See additional resources:
ZINPLAVA is a human monoclonal antibody that binds to Clostridium difficile toxin B indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.
ZINPLAVA is not indicated for the treatment of CDI. ZINPLAVA is not an antibacterial drug. ZINPLAVA should only be used in conjunction with antibacterial drug treatment of CDI.
Before prescribing ZINPLAVATM (bezlotoxumab), please read the Prescribing Information. The Patient Information also is available.